OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:24 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

NCT02975349 · EMD Serono Research & Development Institute, Inc. · PHASE2 · terminated · last registry update 2025-05-14 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.”–Registry record, EMD Serono Research & Development Institute, Inc.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against BTK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision